Stem cell differentiation and diabetic therapy
Liu H,Xue WJ,Feng XS
DOI: https://doi.org/10.3321/j.issn:1673-8225.2007.37.039
2007-01-01
Abstract:BACKGROUND: For diabetic patients, who loss islet cell's function, the most fundamental therapy method is pancreatic or islet transplantation, but all these face the problem of insufficient source and the need of taking immunosuppressants in all their life. OBJECTIVE: To make an adequate knowledge of the stem cells which having the strong abilities of differentiation into insulin-producing cells (IPCs) and its use in diabetic substitutive therapy. RETRIEVE STRATEGY: Researcher of this review searched the Pubmed, ISI Web of Knowledge, Blackwell Synergy Database on computer for the pertinent literature in English between January 2000 and December 2006, using the key words of "stem cells, insulin producing cells, diabetes". Simultaneously, China Journal Full-text Database (CJFD) was undertaken to identify pertinent literature published from January 2000 to December 2006 with the same key words in Chinese, and reading some book related to stem cells in Chinese. 111 articles were checked firstly. Inclusive criteria included the related articles containing human/mouse embryonic or adult stem cells induced into IPCs with different methods such as gene modification, sequential inducing factor and so on, while exclusive criteria included the non-randomized trials reviews, Meta analysis and duplication of one study. LITERATURE EVALUATION: Literature source is major in analysis of articles related to human/mouse embryonic or adult stem cells induced into IPCs. Totally 30 articles were selected, in which one was review and the others were clinical or fundamental empirical study. DATA SYNTHESIS: ①Stem cell undoubtedly become the best semen cell of beta cells because of the extreme self-renewal and the multi-directional differentiation potency. ②A large number of reports have now demonstrated that human or mouse embryonic stem cells (ESCs) can be differentiated into cells with an insulin-expressing phenotype, either by genetic manipulation or by permitting spontaneous differentiation followed by culture under selective conditions. ③Obviously, the more directive way obtaining the substitute of beta cell is to expand and induce pancreas stem cell. But using this method in clinic, there may be some work to do, including finding the optimal project for expanding and inducing and the optimal transplantation position. ④Progenitor cells from tissues other than the pancreas have also received considerable attention, such as hepatic stem cells and marrow mesenchymal stem cell. ⑤More newer research set about the directional differentiation of bone marrow-derived stem cells, foetus cord blood, cord mesenchymal stem cell, placenta-derived multipotent cells (PMCs) and so on, in order to explore more cells to use in cell substitutive therapy. CONCLUSION: The research of the directional differentiation of beta cells from embryonic and pancreatic stem cells ignite the hope of the diabetic patients, thought the application of stem cells for diabetes is in the stage of animal experiment. The deeper comprehension with the pancreatic henogenesis mechanisms and the molecule regulation mechanism of differentiation of beta cells from stem cells has, the faster the diabetic cell therapy develops.